Colin I Johnston
Overview
Explore the profile of Colin I Johnston including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
2112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chowdhury E, Nelson M, Ernst M, Margolis K, Beilin L, Johnston C, et al.
Am J Hypertens
. 2019 Dec;
33(4):350-361.
PMID: 31807750
Background: Despite readily available treatments, control of blood pressure (BP) with population aging remains suboptimal. Further, there are gaps in the understanding of the management of high BP in the...
2.
McNeil J, Woods R, Nelson M, Murray A, Reid C, Kirpach B, et al.
J Gerontol A Biol Sci Med Sci
. 2019 Jan;
74(5):748.
PMID: 30668672
No abstract available.
3.
McNeil J, Wolfe R, Woods R, Tonkin A, Donnan G, Nelson M, et al.
N Engl J Med
. 2018 Sep;
379(16):1509-1518.
PMID: 30221597
Background: Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. However, its role in the primary prevention of cardiovascular disease is unclear, especially in older persons, who...
4.
McNeil J, Woods R, Nelson M, Reid C, Kirpach B, Wolfe R, et al.
N Engl J Med
. 2018 Sep;
379(16):1499-1508.
PMID: 30221596
Background: Information on the use of aspirin to increase healthy independent life span in older persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend disability-free life...
5.
McNeil J, Nelson M, Woods R, Lockery J, Wolfe R, Reid C, et al.
N Engl J Med
. 2018 Sep;
379(16):1519-1528.
PMID: 30221595
Background: In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did...
6.
Evans R, Johnston C
Clin Exp Pharmacol Physiol
. 2017 Aug;
44(11):1075-1076.
PMID: 28802061
No abstract available.
7.
Johnston C
Blood Press
. 2017 Apr;
9(sup1):9-13.
PMID: 28425795
Angiotensin II type 1 (AT 1 ) receptor blockers, such as candesartan, are attractive alternatives to ACE inhibitors in the treatment of hypertension and cardiovascular disease. Although angiotensin-converting enzyme (ACE)...
8.
McNeil J, Woods R, Nelson M, Murray A, Reid C, Kirpach B, et al.
J Gerontol A Biol Sci Med Sci
. 2017 Mar;
72(11):1586-1593.
PMID: 28329340
Background: There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose...
9.
Chowdhury E, Owen A, Ademi Z, Krum H, Johnston C, Wing L, et al.
Am J Hypertens
. 2013 Nov;
27(2):199-206.
PMID: 24249722
Background: We sought to determine the incidence of newly diagnosed diabetes in treated elderly hypertensive patients and the prognostic impact of diabetes on long-term survival. Methods: The Second Australian National...
10.
Burrell L, Risvanis J, Dean R, Patel S, Velkoska E, Johnston C
J Am Soc Hypertens
. 2012 Dec;
7(1):3-13.
PMID: 23246465
The role of arginine vasopressin (AVP) as a hypertensive hormone remains controversial. We have previously reported that intervention with a V(1A) receptor antagonist in 6-week-old prehypertensive spontaneously hypertensive rats (SHR)...